Alzheimer's disease (AD) is a genetically complex and heterogeneous disorder with
multifaceted neuropathological features, including β-amyloid plaques, neurofibrillary …

Triggering receptors expressed on myeloid cells (TREMs) encompass a family of cell-
surface receptors chiefly expressed by granulocytes, monocytes and tissue macrophages …

Microglia activation is observed in various neurodegenerative diseases. Recent advances in
single-cell technologies have revealed that these reactive microglia were with high spatial …

Recent Aβ-immunotherapy trials have yielded the first clear evidence that removing
aggregated Aβ from the brains of symptomatic patients can slow the progression of …

Neurological and psychiatric diseases have high degrees of genetic and pathophysiological
heterogeneity, irrespective of clinical manifestations. Traditional medical paradigms have …

Microglia are central players in brain innate immunity and have been the subject of
extensive research in Alzheimer's disease (AD). In this review, we aim to summarize the …

Astrocytes and microglia are central players in a myriad of processes in the healthy and
diseased brain, ranging from metabolism to immunity. The crosstalk between these two cell …

Alzheimer's disease (AD) is the most common neurodegenerative disease, resulting in the
loss of cognitive ability and memory. However, there is no specific treatment to …

Human genetics and preclinical studies have identified key contributions of TREM2 to
several neurodegenerative conditions, inspiring efforts to modulate TREM2 therapeutically …

Diseases in the central nervous system (CNS) are often difficult to treat. Antibody-and
protein-based therapeutics hold huge promises in CNS disease treatment. However …